MedTrace Logo

High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure

NCT02823626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2019-05-03

No results posted yet for this study

Summary

Primary Aims

1. Evaluate the safety of high-dose spironolactone in combination of patiromer in acute decompensated heart failure patients.
2. Evaluate the efficacy of high-dose spironolactone in combination of patiromer in causing volume loss and symptom relief in patients with ADHF treated with high-dose spironolactone.

Secondary Aims

1: Evaluate the effect of high-dose spironolactone on urinary sodium excretion and renal function.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

Spironolactone and patiromer

High dose spironolactone with or without patiromer based on the patient's baseline potassium

Sponsors & Collaborators

  • Relypsa, Inc.

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Shweta Bansal · UT Health San Antonio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823626 on ClinicalTrials.gov